Cancer treatment and research communications · 2025
Clinical characteristics and prognostic outcomes in KRAS-mutant non-small cell lung cancer: A real-world study with or without COPD comorbidity.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liao Chen, Wang Yubo, Bi Zhoukui, Chen Huawei, Xu Yu, Hu Defeng, Luo Rui, Wang Jiarui, Xu Zhi, Li Yafei, Bai Li
Аннотация
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is the most prevalent comorbidity among lung cancer patients, but its clinical and prognostic relationship with KRAS-mutant non-small cell lung cancer (NSCLC) remains unclear.
METHODS: This multicenter retrospective cohort study enrolled 163 histologically confirmed KRAS-mutant NSCLC patients, including 59 with COPD and 104 without COPD. Clinical data consisted of baseline characteristics, co-mutation profiles, and survival outcomes were collected and efficacy evaluations. PFS and OS were compared using the Kaplan-Meier method and log-rank test.
RESULTS: The COPD-LC group showed with a higher proportion of KRAS G12C mutations (47.4% vs. 26.2%, P = 0.028) and higher smoking rates (91.5% vs. 65.4%, P <0.001). Additionally, this group had a poorer baseline performance status and a higher Charlson Comorbidity Index. Chemoimmunotherapy significantly improved survival in advanced-stage NSCLC patients (mPFS: 9 vs. 6 months, HR = 0.62, P = 0.022; mOS: 24 vs. 11 months, HR = 0.53, P = 0.023), particularly those with COPD-comorbid lung cancer. Notably, within the COPD-LC subgroup, KRAS G12C-mutant patients achieved significantly longer median PFS compared to non-G12C subtypes (11.5 vs. 5 months, HR = 0.38, P = 0.009) and no significant differences in mPFS or mOS were observed between PS 0-1 and PS 2-3 groups. Co-mutations were identified in 78.6% of patients, with no significant intergroup differences.
CONCLUSION: COPD-comorbid KRAS-mutant NSCLC patients exhibit unique G12C subtype enrichment and distinct clinical features. Chemoimmunotherapy represents an effective first-line strategy for this population, particularly benefiting those with G12C mutations.
METHODS: This multicenter retrospective cohort study enrolled 163 histologically confirmed KRAS-mutant NSCLC patients, including 59 with COPD and 104 without COPD. Clinical data consisted of baseline characteristics, co-mutation profiles, and survival outcomes were collected and efficacy evaluations. PFS and OS were compared using the Kaplan-Meier method and log-rank test.
RESULTS: The COPD-LC group showed with a higher proportion of KRAS G12C mutations (47.4% vs. 26.2%, P = 0.028) and higher smoking rates (91.5% vs. 65.4%, P <0.001). Additionally, this group had a poorer baseline performance status and a higher Charlson Comorbidity Index. Chemoimmunotherapy significantly improved survival in advanced-stage NSCLC patients (mPFS: 9 vs. 6 months, HR = 0.62, P = 0.022; mOS: 24 vs. 11 months, HR = 0.53, P = 0.023), particularly those with COPD-comorbid lung cancer. Notably, within the COPD-LC subgroup, KRAS G12C-mutant patients achieved significantly longer median PFS compared to non-G12C subtypes (11.5 vs. 5 months, HR = 0.38, P = 0.009) and no significant differences in mPFS or mOS were observed between PS 0-1 and PS 2-3 groups. Co-mutations were identified in 78.6% of patients, with no significant intergroup differences.
CONCLUSION: COPD-comorbid KRAS-mutant NSCLC patients exhibit unique G12C subtype enrichment and distinct clinical features. Chemoimmunotherapy represents an effective first-line strategy for this population, particularly benefiting those with G12C mutations.